Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City

February 23, 2011 By Bio-Medicine.Org

BASKING RIDGE, N.J., Feb. 23, 2011 /PRNewswire/ — Regado
Biosciences, a privately held company leading the development of
antithrombotic aptamers with active control agents, announced that
Ellen McDonald, MBA, Senior Vice President and Chief Business
Officer, will be speaking and participating on a panel that will
highlight new and innovative cardiovascular drug therapies at the
2011 RBC Capital Markets Healthcare Conference.  The panel
discussion will be held at the New York Palace Hotel in New York
City on Wednesday, March 2, 2011 at 2:35 p.m. EST in Holmes 1.
 

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company
pioneering a new therapeutic technology with the creation and
development of proprietary controllable aptamer drug systems.
 Each system comprises a nuclease-stabilized RNA aptamer, the
therapeutic effect of which can be reversed partially or completely
in real time by its specific and complementary oligonucleotide
active control agent. This technology is being applied to
injectable antithrombotics (including anticoagulants and
antiplatelet agents) in the acute and sub-acute care cardiovascular
setting, a multi-billion dollar world-wide market in need of drugs
with improved safety profiles and a greater degree of therapeutic
control.  The products in Regado’s pipeline are designed to
act as optimized antithrombotics, uniquely concomitantly minimizing
the risk of ischemia and bleeding, and, by allowing patient
specific tuning of the desired therapeutic effect, providing a safe
and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado’s lead program, the anticoagulant system REG1, consists
of two parenteral agents both administered by IV bolus, the first
being a potent highly selective Factor IXa inhibitor (pegnivacogin,
a.k.a. RB006) and the second being its complementary active control
agent (anivamersen, a.k.a. RB007).  Anivamersen c

‘/>”/>

SOURCE

Related Articles Read More >

TE Connectivity opens global medical device prototyping center in Ireland
Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech